Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120370) titled 'Retrospective real-world study on evaluating the efficacy of disitamab vedotin in treating HER2-positive metastatic urothelial carcinoma using HER2 PET-CT' on March 13.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Huashan hospital, Fudan University
Condition:
Urothelial carcinoma
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2026-03-15
Target Sample Size: disitamab vedotin treatment group:68;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=308970
Published by HT Digital Conten...